Traws Pharma
Phase 1Targeting escape mutations in hematological cancers with first and best in class medicines.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $65M
About
Targeting escape mutations in hematological cancers with first and best in class medicines.
Small Molecules
Funding History
2Total raised:$65M
Series B$40MMar 15, 2021
Series A$25MJun 15, 2019